3 May 2017

Block Listing Application and Review

Verona Pharma plc

Read more

3 May 2017

Grant of Options and RSUs and PDMR Dealings

Grant of Options and RSUs and PDMR Dealings

Read more

2 May 2017

Verona Pharma Announces Closing of Global Offering

LONDON, May 02, 2017 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM:VRP) (NASDAQ:VRNA) (“Verona Pharma”), a clinical-stage biopharmaceutical company focused on developing and commercialising innovative therapeutics for the treatment of respiratory diseases with signific…

Read more

2 May 2017

Closing of Global Offering and Total Voting Rights

THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION FOR THE PURPOSES OF ARTICLE 7 OF REGULATION (EU) NO 596/2014

Read more

2 May 2017

Director/PDMR Shareholding

This is a re-release of the Verona Pharma plc announcement released on 28 April 2017 at 17.40 under RNS No 7827D.

Read more

28 April 2017

Director/PDMR Shareholding

 

Read more

27 April 2017

Pricing of Offering and Approval to List on NASDAQ



Read more

26 April 2017

Verona Pharma Announces Pricing of Global Offering and Approval to List on the NASDAQ Global Market

19 April 2017

Global Offering and Application to List on NASDAQ

RNS Number : 6578C

Read more

18 April 2017

FDA Authorisation to Proceed RPL554 Investigation

THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION FOR THE PURPOSES OF ARTICLE 7 OF REGULATION (EU) NO 596/2014. 

Read more

Targeting unmet needs

384m people worldwide suffer from COPD and 37 years is the median life expectancy of CF patients

Read more about COPD and CF in the unmet needs section of this website

Go

Basic & Clinical Pharmacology & Toxicology

Peer-reviewed publication on dual PDE3/4 inhibitors as novel treatments for COPD

The Lancet Respiratory Medicine

Peer-reviewed paper in the Lancet's highly-respected medication journal

Close

Verona Pharma plc
3 More London Riverside, London SE1 2RE
T: +44 (0)203 283 4200

Linkedin     Email Us